NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

X4 Pharmaceuticals logo
$3.05 +0.22 (+7.77%)
As of 02:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

Advanced

Key Stats

Today's Range
$2.77
▼
$3.05
50-Day Range
$2.45
▼
$3.62
52-Week Range
$2.43
▼
$4.83
Volume
662,921 shs
Average Volume
648,473 shs
Market Capitalization
$302.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25
Consensus Rating
Moderate Buy

Company Overview

X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body.

Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections.

X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.

AI Generated. May Contain Errors.

X4 Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

XFOR MarketRank™: 
1.672850139125 of 5 stars

X4 Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 719th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    X4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    X4 Pharmaceuticals has a consensus price target of $11.25, representing about 279.4% upside from its current price of $2.97.

  • Amount of Analyst Coverage

    X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about X4 Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for X4 Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($0.91) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of X4 Pharmaceuticals is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of X4 Pharmaceuticals is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    X4 Pharmaceuticals has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.13% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 10.86, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    X4 Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    X4 Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    X4 Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, X4 Pharmaceuticals insiders have sold 183.57% more of their company's stock than they have bought. Specifically, they have bought $11,868.00 in company stock and sold $33,654.00 in company stock.

  • Percentage Held by Insiders

    1.13% of the stock of X4 Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about X4 Pharmaceuticals' insider trading history.
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XFOR Stock News Headlines

Brookline Capital Markets Comments on XFOR FY2030 Earnings
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Headlines

XFOR Stock Analysis - Frequently Asked Questions

X4 Pharmaceuticals' stock was trading at $4.00 at the beginning of the year. Since then, XFOR stock has decreased by 25.9% and is now trading at $2.9650.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced its earnings results on Thursday, November, 5th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. The business had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.78 million. X4 Pharmaceuticals had a negative trailing twelve-month return on equity of 49.62% and a negative net margin of 474.74%.

X4 Pharmaceuticals shares reverse split on the morning of Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

X4 Pharmaceuticals (XFOR) raised $40 million in an initial public offering (IPO) on Thursday, November 16th 2017. The company issued 4,000,000 shares at a price of $10.00 per share.

Top institutional investors of X4 Pharmaceuticals include Goldman Sachs Group Inc. (2.36%), State Street Corp (1.74%), Integral Health Asset Management LLC (0.25%) and Russell Investments Group Ltd. (0.22%). Insiders that own company stock include Adam R Craig, John Volpone, David Kirske, Paula Ragan, Mark Baldry, Mary Dibiase, Arthur Taveras and Adam S Mostafa.
View institutional ownership trends
.

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Pfizer (PFE), Sorrento Therapeutics (SRNE) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/05/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XFOR
CIK
1501697
Fax
N/A
Employees
45
Year Founded
2010

Price Target and Rating

High Price Target
$12.00
Low Price Target
$10.00
Potential Upside/Downside
+268.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.20 million
Net Margins
-474.74%
Pretax Margin
-474.71%
Return on Equity
-49.62%
Return on Assets
-30.80%

Debt

Debt-to-Equity Ratio
0.55
Current Ratio
13.22
Quick Ratio
12.86

Sales & Book Value

Annual Sales
$35.11 million
Price / Sales
8.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
2.18

Miscellaneous

Outstanding Shares
99,150,000
Free Float
98,027,000
Market Cap
$302.41 million
Optionable
Optionable
Beta
0.47

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:XFOR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners